Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;97(4):610-620.
doi: 10.1111/cge.13718. Epub 2020 Feb 23.

Molecular characterization of Spanish patients with MECP2 duplication syndrome

Affiliations

Molecular characterization of Spanish patients with MECP2 duplication syndrome

Ainhoa Pascual-Alonso et al. Clin Genet. 2020 Apr.

Abstract

MECP2 duplication syndrome (MDS) is an X-linked neurodevelopmental disorder characterized by a severe to profound intellectual disability, early onset hypotonia and diverse psycho-motor and behavioural features. To date, fewer than 200 cases have been published. We report the clinical and molecular characterization of a Spanish MDS cohort that included 19 boys and 2 girls. Clinical suspicions were confirmed by array comparative genomic hybridization and multiplex ligation-dependent probe amplification (MLPA). Using, a custom in-house MLPA assay, we performed a thorough study of the minimal duplicated region, from which we concluded a complete duplication of both MECP2 and IRAK1 was necessary for a correct MDS diagnosis, as patients with partial MECP2 duplications lacked some typical clinical traits present in other MDS patients. In addition, the duplication location may be related to phenotypic severity. This observation may provide a new approach for genotype-phenotype correlations, and thus more personalized genetic counselling.

Keywords: IRAK1; MECP2 duplication; Methyl-CpG-binding protein 2 (MECP2); Xq28-duplication; genotype-phenotype correlation; hypotonia; intellectual disability; recurrent infections.

PubMed Disclaimer

References

REFERENCES

    1. Ehrhart F, Coort SLM, Cirillo E, Smeets E, Evelo CT, Curfs LMG. Rett syndrome-biological pathways leading from MECP2 to disorder phenotypes. Orphanet J Rare Dis. 2016;11(1):158. https://doi.org/10.1186/s13023-016-0545-5.
    1. Sharma K, Singh J, Frost EE, Pillai PP. MeCP2 in central nervous system glial cells: current updates. Acta Neurobiol Exp (Wars). 2018;78:30-40. https://doi.org/10.21307/ane-2018-007.
    1. Horvath PM, Monteggia LM. MeCP2 as an activator of gene expression. Trends Neurosci. 2018;41(2):72-74. https://doi.org/10.1016/j.tins.2017.11.005.
    1. Villard L. MECP2 mutations in males. J Med Genet. 2007;44(7):417-423. https://doi.org/10.1136/jmg.2007.049452.
    1. Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: Revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944-950. https://doi.org/10.1002/ana.22124.Rett.

Publication types

MeSH terms

Substances

Supplementary concepts